Summary We have investigated the effects of 50 min whole-body hyperthermia (WBH; 15 min equilibration followed by 41°C for 35min) on the toxicity and pharmacokinetics of the radiosensitizer Ro 03-8799 in mice.
The curability of many tumours by radiotherapy may be limited by the presence of radioresistant hypoxic tumour cells. Electron affinic compounds such as the nitroimidazoles act as hypoxic cell radiosensitizers and are also preferentially cytotoxic towards these cells (Adams et al., 1976) . Hyperthermia enhances the tumour cytotoxicity of the 2-nitroimidazole radiosensitizer misonidazole (MISO; 1 -(2-nitroimidazol-1 -yl)-3-methoxy-2-propanol) both in vitro (Stratford and Adams, 1977) and in vivo (Bleehen et al., 1977; George et al., 1977) but also increases its acute lethality in mice (Overgaard, 1979) .
MISO is likely to produce sub-optimal radiosensitization in man because dose-limiting neurotoxicity limits achievable tumour concentrations (see Workman, 1983) . Recent studies have shown that 2-nitroimidazoles substituted with basic side chains are more potent radiosensitizers than MISO in vitro (Smithen et al., 1980) , with shorter half-lives and hence lower tissue exposures in vivo (Williams et al., 1982) . One of these, Ro 03-8799 [oc-[(2-nitro-1-imidazolyl )methyl]-1-piperidineethanol], is now under clinical evaluation (Roberts et al., 1986; Saunders et al., 1984) . The basicity and redox properties of this molecule result in improved radiosensitizing potency both in vitro (Dennis et al., 1985; Watts and Jones, 1985; Smithen et al., 1980) and in vivo (Williams et al., 1982) , together with the achievement of appreciably higher in vivo tumour/plasma ratios compared to MISO (Allen et al., 1984; Roberts et al., 1986) . This has led to the expectation that Ro 03-8799 may offer a significant therapeutic advantage. Since, on the basis of intracellular concentrations (Dennis et al., 1985) , Ro 03-8799 is about 4 times more toxic than MISO towards hypoxic cells (M.E. Watts & M. Woodcock, Personal communication) , there is potential for its use in conjunction with hyperthermia.
Despite considerable interest in the combination of radiosensitizers and other drugs with hyperthermia, there have been very few studies of the effects of heat on nitroimidazole drug pharmacokinetics. We have examined the effects of whole-body hyperthermia (WBH) on the toxicity and pharmacokinetics of Ro 03-8799 in mouse plasma, brain and tumour to address the following questions: (1) Does WBH alter the acute toxicity of Ro 03-8799? (2) Does WBH affect the pharmacokinetics and potential pharmacodynamics of Ro 03-8799? (3) Do the interactions have a pharmacokinetic explanation and/or offer new information on the effects of WBH on drug metabolism?
Materials and methods
Mice and tumours Adult C3H/He mice were obtained from our own breeding colony and from Olac Ltd (Bicester, UK). Males were used in most experiments but females were used occasionally. Mice were allowed food (PRD nuts; Labsure, Poole, Dorset, UK) and water ad lib, and were used at 25-35 g body weight.
The KHT sarcoma was grown in the gastrocnemius muscle of the hind leg as previously described (Twentyman et al., 1979) . Mice were treated bearing tumours in the size range 0.4-0.8g. The method of inducing WBH in mice was similar to that previously described by Honess and Bleehen (1982) . Briefly, unanaesthetised unrestrained mice were enclosed in a wire mesh cage and placed under a fan in an incubator (type C2, Laboratory and Electrical Engineering Co., Nottingham, UK; approximate volume 3.5 m3) set at 44°C. Fresh air was pumped continually into the incubator. Three to six mice were treated per 50min session.
Temperatures were measured using a BAT-12 digital thermometer (±_ 0.1 C) fitted with RET-3 murine rectal probes (Bailey's Instruments, Saddle Brooke, NJ, USA) or fine copper/constantan thermocouples as appropriate. (Chantler et al., 1969 Pharmacokinetic parameters Pharmacokinetic parameters were calculated as described in detail elsewhere (White & Workman, 1980; Workman & Brown, 1981 ) using a one-or two-compartment model with curve stripping as appropriate. Apparent volumes of distribution (Vd,e, and Vdarea) were calculated using established methods (Wagner, 1975 Figure 1 shows the core (rectal) and central tumour temperature of unanaesthetised mice, lightly restrained with string or in perspex jigs, which were subjected to 50min WBH in an incubator set at an air temperature of 44°C. Mice restrained in this way exhibited average core temperatures of 35°C prior to heating. Rectal temperatures increased steadily during the first 15 min of WBH, reaching a stable 41°+ 0.5°C for the rest of the heating period. Tumour core temperatures were 4-50C below rectal values at the start of WBH, but rapidly equilibrated with rectal temperatures after the initial 10min heating. Tumour cooling was also more rapid after WBH as compared to core temperatures. This heat treatment produced an average weight loss of 2.0, 3.9 and 6.4% after 10, 30 and 50min WBH respectively.
Sample preparation
Since some nitroimidazoles cause a decrease in body temperature (Gomer & Johnson, 1979; Workman, 1980) Dvorchik and Vessel, 1978) . (Vde,,) (20.5-26.6) min. Plasma Ro 31-0313 concentrations were consistently higher in WBH treated animals compared to controls and this difference was clearly significant at 20min (P <0.01) but not at later times (P >0.05). Although the change in total AUC was modest, the contribution from the f-phase was in fact increased by 36%, In addition, the apparent volume of distribution (Vdarea) was reduced by 13%. (Walton et al., 1985) we investigated the effects of WBH on GFR using 51Cr EDTA (Chantler et al., 1969) . Figure 6 shows that WBH almost completely inhibits 5tCr EDTA clearance specifically during the heating period, resulting in a two-fold decrease in total plasma clearance from 1.14 to 0.58mlg-'h-'. aSignificantly different from each other (P <0.01). 
Effects of WBH on the N-oxidation of Ro 03-8799 in mice

Discussion
In the present study we show that WBH the acute toxicity of the basic radiosensil mice. We also show that WBH has a Ro 03-8799 pharmacokinetics. It (43C x 60 min) had no effect on p fluorescence (Daly et al., 1984 (Wardman, 1979) . Ro 03-8799 is eliminated rapidly not only by urinary excretion but also by metabolic N-oxidation in both mice (Walton et al., 1985) and man (Roberts et al., 1986; Allen et al., 1984) . The (Smith et al., 1952) , an effect mainly attributed to decreased renal blood flow (Radigan & Robinson, 1950 Reinhold et al., 1985) . Lot alter adriamycin WBH may also decrease tissue pH through stimulation of /2a. In dogs WBH anaerobic glycolysis (see Reinhold et al., 1985 (Magin et al., 1980) as well as other normal rabbit tissues following WBH (Mimnaugh et al., 1978) . In more direct support of our hypothesis we have recently shown that mild hyperthermia (41°C) can enhance benznidazole nitroreduction in vitro (Walton et al., unpublished results) .
We also present evidence of hyperthermia-potentiated oxidative metabolism of Ro 03-8799 to its N-oxide, Ro 31-0313. N-oxidation is regarded as predominantly involving components of the hepatic mixed-function oxidases (MFO) (Bickel, 1969) . We have also shown that hyperthermia (41°C) enhances oxidative 0-demethylation of MISO by MFO in vitro (Walton, Bleehen & Workman, unpublished results) . In contrast Collins and Skibba (1983) , showed using an isolated rat liver perfusion technique, that the t 22S of antipyrine and cyclophosphamide were increased at 42 compared to 37°C, concluding that hyperthermia depressed hepatic MFO activity. This may reflect the different model systems and heat doses employed, as well as the particular drugs and metabolic reactions involved.
The 3-fold increase in Ro 03-8799 acute lethality with WBH is similar to the doubling of MISO acute toxicity by local hyperthermia, where core temperatures approached 41°C (Overgaard, 1979; . The nature of Ro 03-8799 acute toxicity, resulting in death immediately after administration in normothermic mice and during or shortly after WBH in heated mice, is at present unknown. At lethal doses of Ro 03-8799 normothermic mice suffered rapid convulsions characteristic of central nervous system toxicity. This may be related to the acute CNS affect seen with Ro 03-8799 in man (Roberts et al., 1986; Saunders et al., 1984) . Considerable evidence suggests that exposure of the nervous system to nitroimidazoles is correlated to their neurotoxicity (e.g. Brown & Workman, 1980; Conroy et al., 1982) . However, we found brain Ro 03-8799 concentrations were minimally altered by WBH, being substantially less than in unheated animals treated with equitoxic high doses. It seems that the increased lethality cannot be attributed to elevated brain exposure to the parent drug. However, reductive metabolism of nitroimidazoles generates highly reactive and toxic metabolities (Rauth, 1984) . Consequently increased toxicity may result from hyperthermia-enhanced Ro 03-8799 reductive metabolism.
Other organ toxicities also occur, e.g., chronic Ro 03-8799 administration caused severe hepatotoxicity in monkeys (Roche Products, 1982) . WBH tends to produce liver temperatures 1-2°C above core temperatures, also resulting in hepatotoxicity after prolonged exposures (Fletcher et al., 1982) . Thus liver damage may be important with the combination. If different organ toxicities do operate with Ro 03-8799 in unheated and heated animals, correlation with the measured pharmacokinetic parameters would not be expected.
High nitroimidazole doses produce large decreases in mouse core temperature (e.g. Workman, 1980 ) and this has a protective effect on the acute lethality of MISO (Gomer & Johnson, 1979) possibly through decreased metabolic activity. Thus the enhanced toxicity of high doses of Ro 03-8799 with WBH may arise from abolition of the protective hypothermia together with an attendant increase in Ro 03-8799 reductive activation.
In conclusion, WBH substantially increased the acute toxicity of Ro 03-8799. It also increased plasma Ro 03-8799 concentrations, partly as a result of inhibited glomerular filtration. Absolute tumour and brain drug concentrations were unaltered, giving reduced tissue/plasma ratios. These WBH-induced alterations in Ro 03-8799 pharmacokinetics probably contribute to its enhanced toxicity but cannot completely explain it. There was no clear correlation between brain drug levels and increased toxicity. However, WBH did enhance the hepatic N-oxidation of Ro 03-8799 in vivo, and hyperthermia potentiated metabolism, particularly nitroreduction, may be involved in the increased toxicity of this combination. In view of this possibility and the cytotoxic potential of bioreductive metabolism, we are investigating the value of Ro 03-8799 or other bioreductively activated drugs in combination with localised tumour hyperthermia.
